ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES

研究计划：这项提议的目标是发展一家生殖泌尿外科 NYPH的肿瘤学计划用于治疗泌尿系肿瘤患者 涉及激活最先进的临床试验，执行 以实验室为基础的研究将增加我们对这些问题的理解 疾病导致治疗方法的改进，并指导初级临床医生 在以病人为中心的研究方法上。具体目标是 1)为肾脏疾病患者进行临床和翻译试验 癌症，包括维甲酸脂质体的生物治疗研究 加干扰素和单抗；2)进行临床和 前列腺癌患者的翻译试验，包括对 识别前列腺特异性膜抗原(PSMA)的单抗muJ591和 维甲酸脂质体对生化(PSA)复发的影响 包括化疗在内的膀胱癌患者的临床试验 患有转移性疾病或复发风险高的患者 (辅助剂)；和4)：指导肿瘤内科研究员和初级教员 临床和转化性试验的设计和实施。这一奖项将允许 纳努斯博士保护了成功完成这些目标的时间。

Research Plan: The objectives of this proposal are to develop a Genitourinary Oncology Program at NYPH for the treatment of patients with urological tumors involving the activation of state of the art clinical trials, performing laboratory-based studies which will increase our understanding of these diseases leading to improved therapies, and to instruct beginning clinicians in the methodologies of patient-oriented research. The specific aims are 1) to conduct clinical and translational trials for patients with renal cancer, including the study of biologic therapies with liposomal tretinoin plus interferon, and monocloncal antibodies (mAb); 2) To conduct clinical and translational trials for patients with prostate cancer, including the study of mAb muJ591 which recognizes prostate specific membrane antigen (PSMA), and the effects of liposomal tretinoin on biochemical (PSA) relapse; 3) To conduct clinical trials for patients with bladder cancer including chemotherapy for patients with metastatic disease or who are at high-risk for relapse (adjuvant); and 4): To mentor medical oncology fellows and junior faculty in clinical and translational trial design and conduct. This award will allow Dr. Nanus protected time to successfully complete these aims.